Experimental and Clinical Physiopathology Research Group CTS-1039, Department of Health Sciences, School of Health Sciences, University of Jaén, Jaén, Spain.
Experimental and Clinical Physiopathology Research Group CTS-1039, Department of Health Sciences, School of Health Sciences, University of Jaén, Jaén, Spain; Department of Nursing, Pharmacology and Physiotherapy, Faculty of Medicine and Nursing, University of Cordoba. IMIBIC, Córdoba, Spain.
Brain Res Bull. 2021 Mar;168:1-7. doi: 10.1016/j.brainresbull.2020.12.008. Epub 2020 Dec 26.
The renin angiotensin system (RAS) is emerging as an important target for the treatment of glioma. We had described that the local RAS is involved in vivo in tumor growth in the rat model of experimental C6 glioma implanted at the subcutaneous region, through the modification of several proteolytic regulatory enzymes of aminopeptidase type.
We analyze RAS-regulating aminopeptidase activities in plasma and brain tissue of control male and female rats and rats with transplacental ethylnitrosourea-induced gliomas.
No differences were found either the mean total number of tumors per animal or the tumor volume between male and female animals. However, we have found increased levels in aspartyl aminopeptidase in both males and females and of aminopeptidase B only in males. On the contrary, decreased levels were found in aminopeptidase N and insulin-regulated aminopeptidase activities in both males and females, whereas aminopeptidase A only decreased in females. Decreased levels of aminopeptidase N, aminopeptidase B and insulin-regulated aminopeptidase were also shown in plasma of only female rats.
Under the complexity of RAS cascade, the changes found suggest the predominant actions of angiotensin III against a decreased action of angiotensin II and angiotensin IV. We conclude that angiotensin peptides are involved in tumor growth in this rat model of glioma and that their role in tumor growth can be analyzed through their corresponding proteolytic regulatory enzymes, which make them new and attractive therapeutic targets beyond the use or angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs).
肾素血管紧张素系统(RAS)正成为治疗神经胶质瘤的重要靶点。我们曾描述过,局部 RAS 通过改变几种氨基肽酶类型的蛋白水解调节酶,参与了实验性 C6 神经胶质瘤在皮下植入大鼠模型中的体内肿瘤生长。
我们分析了雄性和雌性对照组大鼠以及经胎盘乙基亚硝脲诱导的神经胶质瘤大鼠的血浆和脑组织中的 RAS 调节氨基肽酶活性。
雄性和雌性动物之间的平均每只动物肿瘤总数或肿瘤体积均无差异。然而,我们发现雄性和雌性动物的天冬氨酰氨基肽酶水平升高,而只有雄性动物的氨基肽酶 B 水平升高。相反,雄性和雌性动物的氨基肽酶 N 和胰岛素调节的氨基肽酶活性降低,而只有雌性动物的氨基肽酶 A 降低。雄性和雌性动物的血浆中也显示出氨基肽酶 N、氨基肽酶 B 和胰岛素调节的氨基肽酶水平降低。
在 RAS 级联的复杂性下,发现的变化表明血管紧张素 III 的作用占主导地位,而血管紧张素 II 和血管紧张素 IV 的作用降低。我们得出结论,血管紧张素肽参与了这种大鼠神经胶质瘤模型中的肿瘤生长,并且可以通过其相应的蛋白水解调节酶来分析它们在肿瘤生长中的作用,这些酶使它们成为超越血管紧张素转换酶(ACE)抑制剂和血管紧张素受体阻滞剂(ARBs)使用的新的有吸引力的治疗靶点。